Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis

Figures & data

Figure 1. Flow diagram of study selection.

Table 1. Characteristics of the included trials.

Study (first author, years)	E/C	Sample size (M/F)	Age (year)	Intervention and control protocol			Reported outcomes (evaluation criteria)
				Experimental	Aidi(D/D/C)	Control
Chen 2016	30/30	36/24	42–76	Aidi + GP	50 ml × 8 d × 2	GP	ORR (WHO), DCR (WHO)
Chen and Wang 2014	40/40	52/28	41.6 ± 4.72	Aidi + GP	60 ml × 42 d × 1	GP	ORR (WHO), DCR (WHO), QOL
Ding et al. 2011	18/22	27/13	53	Aidi + GP	50 ml × 10 d × 2	GP	ORR (WHO)
Fan et al. 2011	41/38	54/25	E: 39 − 71 C: 41 − 73	Aidi + GP	50 ml × 21 d × 2–4	GP	ORR (WHO), DCR (WHO), QOL
Fang 2016	45/45	NR	E: 40 − 70 C: 43 − 69	Aidi + GP	50 ml × 10 d × 2	GP	ORR (WHO), DCR (WHO), ADRs (CTCAE3.0)
Fu 2012	35/35	NR	70.2 ± 5.6	Aidi + GP	50 ml × 14 d × 2	GP	ORR (WHO), DCR (WHO)
Geng et al. 2020	45/45	61/29	E: 66.95 ± 14.19 C: 66.58 ± 14.26	Aidi + GP	50 ml × 14 d × 4	GP	ORR (NR), DCR (NR), ADRs (NR)
Guo 2020	51/51	58/44	E: 57.52 ± 2.17 C: 58.18 ± 3.11	Aidi + GP	60 ml × 14 d × 4	GP	ADRs (NR)
Han et al. 2015	36/36	39/33	E: 55.4 ± 3.7 C: 54.9 ± 4.2	Aidi + GP	50 ml × 28 d × 3	GP	ORR (WHO), DCR (WHO), ADRs (WHO)
He et al. 2011	29/23	29/23	E: 21 − 73 C: 29 − 74	Aidi + GP	50–100 ml × 15 d × 2–3	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Hong et al. 2010	90/70	82/78	38–70	Aidi + GP	60 ml × 14 d × 2	GP	ORR (WHO), DCR (WHO), QOL
Huang et al. 2017	39/40	46/33	E: 58.46 ± 7.43 C: 58.74 ± 7.68	Aidi + GP	60 ml × 21 d × 3	GP	ORR (RECIST), DCR (RECIST), ADRs (WHO)
Jiang et al. 2011	32/30	39/23	E: 68.2 C: 67.6	Aidi + GP	100 ml × 14 d × 2	GP	ORR (NR), DCR (NR)
Ju et al. 2013	34/34	36/32	E: 69.5 ± 8.1 C: 67.4 ± 7.8	Aidi + GP	50 ml × 14 d × 2	GP	ORR (WHO), DCR (WHO), QOL
Lai 2013	70/70	73/67	E: 49 − 79 C: 45 − 75	Aidi + GP	50 ml × 14 d × 2	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Li et al. 2016	35/35	43/27	E: 62.15 ± 3.64 C: 64.09 ± 3.14	Aidi + GP	100 ml × 14 d × 2	GP	ORR (NR), DCR (NR), QOL, ADRs (NR)
Li and Yang 2014	27/27	32/22	62.3 ± 4.9	Aidi + GP	50 ml × 8–10 d × 4	GP	ORR (RECIST), DCR (RECIST), ADRs (CTCAE3.0)
Li et al. 2008	53/51	73/31	E: 32 − 79 C: 31 − 77	Aidi + GO	60 ml × 10 d × 2	GO	ORR (WHO), DCR (WHO), QOL, ADRs (NR)
Li et al. 2010	36/36	39/33	E: 29 − 75 C: 32 − 73	Aidi + GP	50–100 ml × 15 d × 2–3	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Li et al. 2016	47/47	53/41	E: 55.2 ± 2.4 C: 53.4 ± 2.7	Aidi + GP	50–100 ml × 28 d × 1	GP	ORR (WHO), DCR (WHO), ADRs (WHO)
Liu et al. 2010	32/32	37/27	E: 45 − 73 C: 47 − 75	Aidi + GP	50 ml × 14 d × 4	GP	ORR (WHO), DCR (WHO), ADRs (NR)
Liu and Zhang 2014	24/24	30/18	35–80	Aidi + GP	60 ml × 21 d × 2	GP	QOL (NR)
Liu et al. 2019	44/44	54/34	E: 59.11 ± 6.59 C: 59.07 ± 6.45	Aidi + GP	50 ml × 5 d × 2	GP	ORR (NR), DCR (NR)
Lu et al. 2006	33/29	41/21	E: 29 − 75 C: 31 − 76	Aidi + GP	50–100 ml × 10–15 d × 3	GP	ORR (WHO), DCR (WHO), QOL, ADRs (NR)
Lv et al. 2009	29/29	37/21	E: 65 − 72 C: 60 − 75	Aidi + GP	50 ml × 15 d × 2	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Lv et al. 2018	30/30	35/25	E: 67.5 ± 13.6 C: 66.9 ± 15.2	Aidi + GP	50 ml × 14 d × 1	GP	ORR (NR), DCR (NR)
Lv et al. 2009	30/30	42/18	45–70	Aidi + GP	80 ml × 10 d × 2	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Ma 2017	42/42	55/29	E: 60.13 ± 8.43 C: 59.49 ± 8.76	Aidi + GP	50 ml × 28 d × 4	GP	ORR (NR), DCR (NR), ADRs (NR)
Ma and Jiang 2016	33/35	39/29	E: 68.9 ± 10.4 C: 66.9 ± 10.6	Aidi + GP	60 ml × 14 d × 1	GP	ORR (WHO), DCR (WHO), ADRs (NR)
Ma et al. 2010	24/24	39/9	E: 58.7 C: 59.1	Aidi + GP	40 ml × 10 d × 2	GP	ORR (WHO), DCR (WHO), ADRs (WHO)
Ning et al. 2015	31/31	49/13	E: 47 − 75 C: 45 − 72	Aidi + GP	50 ml × 14 d × 3	GP	ORR (WHO), DCR (WHO), ADRs (WHO)
Pan et al. 2012	38/42	55/25	E: 39 − 79 C: 42 − 81	Aidi + GP	50 ml × 14 d × 3	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Pei 2012	40/40	47/33	E: 57.1 ± 8.3 C: 59.2 ± 6.7	Aidi + GP	50 ml × 8 d × 2	GP	ORR (RECIST), DCR (RECIST)
Shi et al. 2010	28/28	47/9	E: 61.5 C: 60.5	Aidi + GP	50 ml × 14 d × 2	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Song et al. 2009	30/30	36/24	53–76	Aidi + GP	50 ml × 14 d × 2	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Su and Zhang 2019	41/41	54/28	E: 56.24 ± 9.07 C: 55.08 ± 8.13	Aidi + GP	150 ml × 21 d × 4–6	GP	ORR (RECIST), DCR (RECIST), QOL, ADRs (NR)
Sun et al. 2012	34/34	42/26	E: 60 − 83 C: 62 – 86	Aidi + GP	50 ml × 10 d × 2	GP	ORR (RECIST), DCR (RECIST), QOL, ADRs (CTCAE3.0)
Wang 2012	25/24	35/14	E: 56.8 ± 9.1 C: 57.8 ± 10.2	Aidi + GP	60 ml × 14 d × 3	GP	ORR (WHO), DCR (WHO), ADRs (NR)
Wang and Peng 2012	36/36	46/26	32 − 74	Aidi + GP	80 ml × 10 d × 4	GP	ORR (RECIST), DCR (RECIST), QOL, ADRs (WHO)
Wen 2014	45/45	64/26	E: 67.8 ± 6.4 C: 68.3 ± 5.7	Aidi + GP	50 ml × 21 d × 2	GP	ORR (RECIST), DCR (RECIST), QOL, ADRs (CTCAE3.0)
Wen et al. 2009	38/38	52/24	32–77	Aidi + GP	50 ml × 8–10 d × 2	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Wu and Chen 2017	67/68	83/52	E: 59.4 ± 5.5 C: 58.6 ± 5.2	Aidi + GP	100 ml × 10 d × 4	GP	ORR (NR), DCR (NR), ADRs (NR)
Wu et al. 2017	109/109	137/78	E: 54.3 ± 14.2 C: 53.1 ± 13.1	Aidi + GP	50 ml × 14 d × 3	GP	ADRs (NR)
Xiao 2006	39/29	48/20	65–79	Aidi + GP	60–80 ml × 10d × 2	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Yang et al. 2008	30/27	39/18	34–82	Aidi + GP	80 ml × 8 d × 2	GP	ORR (WHO), DCR (WHO), QOL
Zhang 2009	32/31	44/19	E: 32 − 79 C: 31 – 71	Aidi + GP	80 ml × 14 d × 2	GP	ORR (WHO), DCR (WHO), ADRs (WHO)
Zhang 2012	41/42	63/20	E: 57.2 ± 9.4 C: 58.2 ± 10.3	Aidi + GP	60 ml × 14 d × 3	GP	ORR (WHO), DCR (WHO), ADRs (NR)
Zhang S 2016	25/25	NR	NR	Aidi + GP	50 ml × 10 d × 4	GP	ORR (RECIST), DCR (RECIST)
Zhang X 2016	19/19	21/17	E: 55.68 ± 4.54 C: 54.62 ± 5.95	Aidi + GP	50 ml × 30 d × 1	GP	ORR (WHO), DCR (WHO), ADRs (NR)
Zhang et al. 2018	40/40	43/37	E: 54.67 ± 3.24 C: 54.71 ± 3.26	Aidi + GP	60 ml × 10 d × 2	GP	ADRs (WHO)
Zhang and Wang 2008	39/35	43/31	E: 21 − 73 C: 29 – 74	Aidi + GP	50–100 ml × 15 d × 2–3	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)
Zhang et al. 2018	52/52	64/40	E: 62.24 ± 2.70 C: 62.19 ± 2.47	Aidi + GP	60–100 ml × 10 d × 4	GP	ORR (NR), DCR (NR), ADRs (NR)
Zhao and Li 2019	43/43	55/31	E: 64.02 ± 2.34 C: 63.26 ± 2.57	Aidi + GP	50 ml × 21 d × 2	GP	ORR (NR), DCR (NR)
Zou et al. 2006	42/39	56/25	E: 37 − 72 C: 35 – 73	Aidi + GP	80 ml × 14 d × 3	GP	ORR (WHO), DCR (WHO), QOL, ADRs (WHO)

Note: NSCLC: non-small cell lung cancer; E/C: experimental group (Aidi injection plus gemcitabine-based chemotherapy)/control group (gemcitabine-based chemotherapy); M/F: male/female; GP: gemcitabine and cisplatin; GO: gemcitabine and oxaliplatin; Aidi(D/D/C): Aidi injection (Dose/Days/ Cycles); WHO: World Health Organisation guidelines for solid tumour responses; RECIST: Response Evaluation Criteria in Solid Tumours; CTCAE: Common terminology criteria for adverse events version; ORR: objective response rate; DCR: disease control rate; QOL: quality of life; ADRs: adverse drug reactions.

Figure 2. Risk of bias of included studies. (A) Risk of bias summary: judgments about each bias item for each study; (B) Risk of bias summary graph.

Figure 3. Meta-analysis on the ORR in the Aidi plus GBC vs. GBC.

Figure 4. Meta-analysis on the DCR in the Aidi plus GBC vs. GBC.

Figure 5. Meta-analysis on the QOL in the Aidi plus GBC vs. GBC.

Table 2. Meta-analysis results of ADRs.

Outcomes	Trials	Aidi plus GBC (Evens/Total)	GBC (Evens/Total)	SM	RR (95% CI)	I^2	p
Gastrointestinal toxicity	33	458/1352	703/1332	FEM	0.64 (0.59, 0.70)	27%	<0.00001^*
Thrombocytopenia	17	134/653	198/647	REM	0.62 (0.46, 0.83)	58%	0.001^*
Neutropenia	38	480/1535	749/1513	FEM	0.62 (0.57, 0.68)	33%	<0.00001^*
Liver injury	20	123/869	215/861	FEM	0.57 (0.47 0.69)	0%	<0.00001^*
Renal injury	7	27/325	56/317	FEM	0.48 (0.31, 0.74)	0%	0.0008^*
Anaemia	7	61/370	105/369	FEM	0.58 (0.44, 0.76)	0%	0.0001^*

Note: Aidi: Aidi injection; GBC: gemcitabine-based chemotherapy; RR, relative ratio; REM: random-effects model; FEM: fixed-effects model. *Favours Aidi plus GBC group with statistical significance.

Figure 6. Sensitivity analysis. (A) ORR; (B) DCR; (C) QOL; (D) Gastrointestinal toxicity; (E) Thrombocytopenia; (F) Neutropenia; (G) Liver injury; (H) Renal injury; (I) Anaemia.

Table 3. Subgroups analysis of ORR and DCR.

Subgroups	Objective response rate (ORR)						Disease control rate (DCR)
	Trials	Study event rates		RR (95% CI)	I^2	p	Trials	Study event rates		RR (95% CI)	I^2	p
		Aidi plus GBC	GBC					Aidi plus GBC	GBC
Totality	50	1041/1894	735/1848	1.38 (1.29, 1.48)	0%	<0.00001	49	1604/1876	1355/1826	1.15 (1.12, 1.19)	0%	<0.00001*
Subgroups analysis via doses
Aidi injection (40 ml/times)	1	11/24	8/24	1.38 (0.67, 2.81)	NA	0.38	1	19/24	17/24	1.12 (0.80, 1.55)	NA	0.51
Aidi injection (50 ml/times)	26	478/929	359/934	1.34 (1.21, 1.48)	0%	<0.00001	25	772/911	676/912	1.14 (1.09, 1.20)	0%	<0.00001*
Aidi injection (60 ml/times)	7	180/321	123/302	1.36 (1.16, 1.61)	0%	0.0002	7	269/321	214/302	1.18 (1.08, 1.29)	0%	0.0002*
Aidi injection (80 ml/times)	5	100/170	63/163	1.52 (1.20, 1.92)	24%	0.004	5	147/170	114/163	1.23 (1.10, 1.38)	0%	0.0003*
Aidi injection (50–150 ml/times)	11	272/450	182/425	1.42 (1.25, 1.62)	0%	<0.00001	11	397/450	334/425	1.12 (1.06, 1.19)	0%	<0.0001*
Subgroups analysis via treatment time
10–30 days	27	517/996	389/964	1.28 (1.16, 1.41)	0%	<0.00001	26	838/984	704/948	1.15 (1.10, 1.20)	0%	<0.00001*
31–60 days	18	422/699	284/687	1.46 (1.31, 1.63)	0%	<0.00001	19	622/734	532/719	1.14 (1.09, 1.21)	0%	0.0002*
>60 days	5	102/199	62/197	1.63 (1.28, 2.08)	0%	<0.0001	4	144/158	119/159	1.22 (1.10, 1.35)	0%	<0.00001*

Note: Aidi: Aidi injection; GBC: gemcitabine-based chemotherapy; RR, relative ratio; CI: confidence interval.

*Favours Aidi plus GBC group with statistical significance.

Figure 7. Trial sequential analysis. (A) ORR; (B) DCR; (C) QOL; (D) Gastrointestinal toxicity; (E) Thrombocytopenia; (F) Neutropenia; (G) Liver injury; (H) Renal injury; (I) Anaemia.

Figure 8. Meta-regression analysis of ORR and DCR.

Figure 9. The publication bias analysis.

Table 4. GRADE evidence profile of clinical efficacy and safety.

Out comes (trials)	Quality assessment					No of patients		Clinical efficacy and safety		Quality
	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Aidi plus GBC	GBC	Relative ratio (95% CI)	Absolute effects
ORR (50)	Serious^a	No serious	No serious	No serious	None	1041/1894 (55.0%)	735/1848 (39.8%)	1.38 (1.29–1.48)	151 more per 1000 (from 115 more to 191 more)	⊕⊕⊕ moderate
DCR (49)	Serious^a	No serious	No serious	No serious	None	1604/1876 (85.5%)	1355/1826 (74.2%)	1.15 (1.12–1.19)	111 more per 1000 (from 89 more to 141 more)	⊕⊕⊕ moderate
QOL (24)	Serious^a	No serious	No serious	No serious	None	565/960 (58.9%)	311/909 (34.2%)	1.71 (1.54–1.89)	243 more per 1000 (from 185 more to 304 more)	⊕⊕⊕ moderate
Gastrointestinal toxicity (33)	Serious^a	No serious^b	No serious	No serious	None^c	458/1352 (33.9%)	703/1332 (52.8%)	0.64 (0.59–0.70)	190 fewer per 1000 (from 158 fewer to 216 fewer)	⊕⊕⊕ moderate
Thrombocytopenia (17)	Serious^a	No serious^b	No serious	No serious	None	134/653 (20.5%)	198/647 (30.6%)	0.64 (0.54–0.77)	110 fewer per 1000 (from 70 fewer to 141 fewer)	⊕⊕⊕ moderate
Neutropenia (37)	Serious^a	No serious^b	No serious	No serious	None^c	457/1335 (34.2%)	702/1313 (53.5%)	0.63 (0.58–0.69)	198 fewer per 1000 (from 166 fewer to 225 fewer)	⊕⊕⊕ moderate
Liver injury (20)	Serious^a	No serious	No serious	No serious	None^c	123/869 (14.3%)	215/861 (25.0%)	0.57 (0.47–0.69)	107 fewer per 1000 (from 77 fewer to 132 fewer)	⊕⊕⊕ moderate
Renal injury (7)	Serious^a	No serious	No serious	Serious^d	None	27/325 (8.3%)	56/117 (13.3%)	0.48 (0.31–0.74)	92 fewer per 1000 (from 46 fewer to 122 fewer)	⊕⊕ low
Anaemia (7)	Serious^a	No serious	No serious	Serious^d	None	61/370 (16.5%)	105/369 (28.5%)	0.58 (0.44–0.76)	120 fewer per 1000 (from 68 fewer to 159 fewer)	⊕⊕ low

Note: Aidi: Aidi injection; GBC: gemcitabine-based chemotherapy; RR, relative ratio; CI: confidence interval; ORR: objective response rate; DCR: disease control rate; QOL: quality of life.

^aMost domain trials mentioned applying a randomisation methodology, but few of included study specified the method and none of the trials specified the methods of allocation concealment and the blinding procedures. Therefore, evidence was rated down by only one level.

^bConsiderable heterogeneity and the results had good robustness. Not rated down

^cNot rated down. The ADRs were over-estimated.

^dThe total sample size did not reach the optimal information size, and the sample size for each indicator was less than 300 cases, and the evidence was rated down by one level.

Chen Y. 2016. Effect of Aidi injection combined with chemotherapy on serum VEGF-C and CYFR21-1 levels in patients with advanced non-small cell lung cancer. Chin J Clin Ration Drug Use. 9:5–6.

 Google Scholar

Chen R, Wang W. 2014. Effect analysis of Aidi injection combined with GP regimen in treatment of advanced non-small cell lung cancer. Chin Modern Med. 21:84–85,91.

 Google Scholar

Ding P, Ge H, Li M, Zhu M. 2011. Clinical study of Aidi combined with GP regimen in the treatment of advanced non-small cell lung cancer. J Clinic Pulm Med. 16:1802–1803.

 Google Scholar

Fan S, Peng L, Qi X. 2011. Clinical observation of Aidi injection combined with chemotherapy for advanced non-small cell lung cancer. Zhejiang J Integr Tradit West Med. 21:232–233.

 Google Scholar

Fang L. 2016. Aidi injection combined with GP regimen for curative effect observation III∼IV stage non-small cell lung cancer. J Med Forum. 37:74–75.

 Google Scholar

Fu L. 2012. Clinical effect analysis of Aidi injection combined with GP chemotherapy in elderly patients with advanced non-small cell lung cancer. Guide Chin Med. 10:466.

 Google Scholar

Geng K, Dong J, Su H, Dai C, Chen J, Yue X. 2020. Efficacy and safety of Aidi injection combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Henan Med Res. 29:2231–2232.

 Google Scholar

Guo X. 2020. Effect analysis of Aidi injection combined with GP regimen in treatment of advanced NSCLC. Pract Clin J Integr Tradit West Med. 20:104–105.

 Google Scholar

Han R, Wang A, Yang G, Yang Y, Liu B, Cao X, Li N, Zhou Q, Yan Y. 2015. Effect of Aidi injection on chemotherapy efficacy and immune function of advanced non-small cell lung cancer. Chin J Geron. 35:4878–4879.

 Google Scholar

He W, Wu L, Yu C, Song Y. 2011. Clinical observation of GP regimen combined with Aidi in the treatment of advanced non-small cell lung cancer. Acta Academiae Med CPAF. 20:296–297.

 Google Scholar

Hong Y, Wang J, Jiao Z. 2010. Clinical observation of Aidi injection combined with GP regimen in treatment of advanced non-small cell lung cancer. Chin J Clin Oncol Rehabil. 17:247–249.

 Google Scholar

Huang W, Zheng J, Guo B. 2017. The clinical effects and influence on the immune function of Aidi injection combined with GP regimen in the treatment of patients with non-small cell lung cancer. J Med Theor Pract. 30:995–997.

 Google Scholar

Jiang S, Mao X, Hong J. 2011. Clinical research on 60 cases of non-small cell lung cancer treated by Aidi injection combined with chemotherapy. Zhejiang J Integr Tradit West Med. 21:24–26.

 Google Scholar

Ju S, Li C, Xu Y. 2013. Clinical efficacy of Aidi injection combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer in the elderly. Strait Pharm. 25:206–207.

 Google Scholar

Lai L. 2013. Efficacy of GP chemotherapy combined with Aidi injection in the treatment of advanced senile non-small cell lung cancer. Modern J Integr Tradit West Med. 22:257–258.

 Google Scholar

Li J, Yang Z, Song X, Jian Q, Sun X, Zhang H, LIu W. 2016. Short-term efficacy and safety of Aidi injection adjuvant GP regimen for advanced non-small cell lung cancer. Hebei Med. 38:1345–1347.

 Google Scholar

Li J, Yang G. 2014. Clinical efficacy of Aidi injection combined with GP regimen in advanced non-small cell lung cancer. Heilongjiang Med J. 38:447–448.

 Google Scholar

Li H, Dong L, Li Y, Fu S. 2008. Aidi injection combined with GO regimen in the treatment of advanced non-small cell lung cancer. Zhejiang J Integr Tradit West Med. 18:473–475.

 Google Scholar

Li Z, Liu X, Yuan L. 2010. Observation on the efficacy of eti combined with gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. J Community Med. 8:23–24.

 Google Scholar

Liu L, Liu Y, Zhang T. 2010. Short-term efficacy of Aidi injection combined with chemotherapy for advanced non-small cell lung cancer. Natl Med Fron Chin. 5:46–46.

 Google Scholar

Liu Z, Zhang C. 2014. Aidi injection combined with GP regimen in the treatment of advanced non-small cell lung cancer: a randomized parallel control study. J Pract Trad Chin Internal Med. 28:65–67.

 Google Scholar

Liu H, Nie Q, Lu Y, Liu X. 2019. Clinical efficacy of Aidi injection combined with GP regimen in advanced non-small cell lung cancer and its effect on serum VEGF expression and immune function. Jiangxi J Tradit Chin Med. 50:42–44.

 Google Scholar

Lu C, Wang H, Wang J. 2006. Clinical observation of Aidi injection combined with chemotherapy for advanced non-small cell lung cancer. Health Horizon. 14:30–31.

 Google Scholar

Lv D, Guo Q, Qiu Y. 2009. Clinical research on 30 cases of advanced non-small cell lung cancer treated by Aidi injection combined with chemotherapy. Jiangxi J Tradit Chin Med. 40:47–48.

 Google Scholar

Lv W, Hu S, Xiong G, Xiong H. 2018. The clinical effects and influence on the immune function of chemotherapy combined with Traditional Chinese and Western medicine on non-small cell lung cancer patients. Anti-Infection Pharmacy. 15:544–547.

 Google Scholar

Ma M. 2017. Effect of Aidi injection combined with GP chemotherapy on patients with advanced NSCLC with QI-Yin deficiency and its influence on immune function and coagulation function. Asia-Pacific Tradit Med. 13:108–110.

 Google Scholar

Ma Y, Jiang X. 2016. Effect of Aidi injection combined with GP regimen on patients with non-small cell lung cancer. Pract J Cardiac Cereb Pneum Vasc Dis. 24:89–92.

 Google Scholar

Ma J, Zhan Y, Huang C. 2010. Efficacy of Aidi injection combined with chemotherapy in the treatment of non-small cell lung cancer. Guangxi Med J. 32:932–933.

 Google Scholar

Ning S, Zhan B, Xu H. 2015. Aidi injection combined with GP regimen in the treatment of advanced non-small cell lung cancer with EGFR-TKI acquired resistance. Drugs Clin. 30:691–695.

 Google Scholar

Pan C, Chu D, Hu Z, Guo S, Du Y. 2012. Efficacy of GP regimen combined with Aidi injection in the treatment of advanced non-small cell lung cancer. Chin J Clin Med. 19:613–615.

 Google Scholar

Pei W. 2012. Effect of Aidi injection combined with GP regimen on serum VEGF in patients with advanced non-small cell lung cancer. Chin Med Her. 09:99–100.

 Google Scholar

Shi X, Yu A, Yang Y, Jin X, Dai L, Zhang T, Wang M, Wang Z, Pan W. 2010. Clinical observation of Aidi injection combined with chemotherapy for advanced non-small cell lung cancer. Zhejiang J Integr Tradit West Med. 20:747–748.

 Google Scholar

Song Z, Liu X, Zhang H, Shang D, Xu Y. 2009. Efficacy of Aidi injection combined with GP regimen in the treatment of advanced non-small cell lung cancer. Med Res Educ. 26:36–37.

 Google Scholar

Su D, Zhang X. 2019. Clinical observation of Aidi injection combined with GP chemotherapy in the treatment of non-small cell lung cancer. J Basic Clin Oncol. 32:31–34.

 Google Scholar

Sun J, Xu P, Shi D, Cao B. 2012. Clinical efficacy evaluation of Aidi injection combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer in the elderly. J Jilin Univ. 38:151–154.

 Google Scholar

Wang J. 2012. Efficacy of Aidi injection combined with GP regimen in the treatment of non-small cell lung cancer. J Clin Pulm Med. 17:312–313.

 Google Scholar

Wang Y, Peng L. 2012. Clinical study of Aidi combined with GP regimen in the treatment of advanced non-small cell lung cancer. Chin Community Doct. 14:231.

 Google Scholar

Wen H. 2014. Clinical observation of combined Traditional Chinese and Western medicine in the treatment of advanced non-small cell lung cancer in the elderly. Modern J Integr Tradit West Med. 23:2325–2326.

 Google Scholar

Wen K, Li J, Peng D. 2009. Efficacy of Aidi injection combined with GP regimen in the treatment of advanced non-small cell lung cancer. Chin J Basic Med Tradit Chin Med. 15:716–717.

 Google Scholar

Wu T, Chen S. 2017. Feasibility study of Aidi injection combined with chemotherapy in non-small cell lung cancer. Chin Foreign Med Treat. 36:126–127,136.

 Google Scholar

Wu Y, Qu Z, Tao H. 2017. Efficacy of Aidi injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Shanxi J Tradit Chin. 38:883–884.

 Google Scholar

Xiao Y. 2006. Clinical observation of Aidi injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer in the elderly. J Clin Pulm Med. 11:286–287.

 Google Scholar

Yang Q, Chen W, Huang J, Chen X. 2008. Aidi injection combined with chemotherapy in the treatment of advanced lung cancer. Guangming J Chin Med. 23:1760–1761.

 Google Scholar

Zhang L. 2009. Clinical observation of Aidi combined with GP regimen in the treatment of advanced non-small cell lung cancer. J Pract Med. 25:2929–2930.

 Google Scholar

Zhang Y. 2012. Efficacy of Aidi injection combined with GP regimen in the treatment of non-small cell lung cancer. Modern J Integr Tradit West Med. 21:2095–2096.

 Google Scholar

Zhang S. 2016. Short-term and long-term efficacy of Aidi injection in the treatment of advanced lung cancer. J Today Health. 15:46.

 Google Scholar

Zhang X. 2016. Clinical observation of Aidi injection combined with GP regimen in the treatment of non-small cell lung cancer. J Liaoning Univ Tradit Chin Med. 18:173–175.

 Google Scholar

Zhang H, Cai S, Chen J, Chen F. 2018. Feasibility study of Aidi injection combined with chemotherapy in the treatment of non-small cell lung cancer. Chin Conti Med Educ. 9:195–196.

 Google Scholar

Zhang Y, Wang H. 2008. Clinical observation of GCb combined with Aidi in the treatment of advanced non-small cell lung cancer. J Liaoning Univ Tradit Chin Med. 10:73–74.

 Google Scholar

Zhao J, Li J. 2019. Effect of Aidi injection combined with GP regimen in advanced non-small cell lung cancer. Clin Res Pract. 4:117–119.

 Google Scholar

Zou Y, Li J, Luo X. 2006. Clinical observation of Aidi injection combined with GP chemotherapy in the treatment of advanced lung cancer. Hubei J Tradit Chin Med. 28:33–34.

 Google Scholar